NCT00568191

Brief Summary

The Cirrus OCT provides due to the spectral domain technology a 2-fold resolution than Stratus OCT generated in a comparable amount of time. Due to this higher resolution the retinal surface and the retinal pigment epithelium can be identified more clearly, a significantly reduced number of algorithm failures is expected

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2007

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2007

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2007

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

December 4, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

December 5, 2007

Completed
Last Updated

December 5, 2007

Status Verified

December 1, 2007

First QC Date

December 4, 2007

Last Update Submit

December 4, 2007

Conditions

Age-Related Macular DegenerationChoroidal Neovascularization

Keywords

Age-related macular degenerationchoroidal neovascularizationStratus OCTCirrus OCT

Outcome Measures

Primary Outcomes (1)

  • Number of algorithm failures assessed by Stratus OCT versus Cirrus OCT in the horizontal central line

    only 1 examination

Secondary Outcomes (1)

  • Number of algorrithm failures in Stratus versus Cirrus OCT assessed in the whole scan

    1 examination

Study Arms (2)

1

retinal thickness program Stratus OCT software 4.0

2

retinal cube 200x200 program of Cirrus OCT

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients aged \> 55 years of either sex presenting with age-related macular degeneration

You may qualify if:

  • Age\>55 years
  • Age-related macular degeneration

You may not qualify if:

  • Not consented patients

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery

Vienna, Vienna, A1030, Austria

RECRUITING

Related Publications (1)

  • Krebs I, Falkner-Radler C, Hagen S, Haas P, Brannath W, Lie S, Ansari-Shahrezaei S, Binder S. Quality of the threshold algorithm in age-related macular degeneration: Stratus versus Cirrus OCT. Invest Ophthalmol Vis Sci. 2009 Mar;50(3):995-1000. doi: 10.1167/iovs.08-2617. Epub 2008 Nov 21.

    PMID: 19029035DERIVED

MeSH Terms

Conditions

Macular DegenerationChoroidal Neovascularization

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye DiseasesChoroid DiseasesUveal DiseasesNeovascularization, PathologicMetaplasiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Ilse Krebs

    Ludwig Boltzmann Institute of Retinology and Biomicroscopic Lasersurgery

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ilse Krebs, MD

CONTACT

+43171165Ilse.Krebs@wienkav.at

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 4, 2007

First Posted

December 5, 2007

Study Start

October 1, 2007

Study Completion

December 1, 2007

Last Updated

December 5, 2007

Record last verified: 2007-12

Locations

AU(1)